Aetna Rolls Out Coverage For Rare Disease Gene Therapies
Aetna is launching a new network to cover gene therapies for inherited retinal disease and spinal muscular atrophy. The insurer expects gene therapies to add $45 billion to healthcare costs between 2020 and 2024 if the FDA approves all other therapies currently in the pipeline.
This article is available to Insider Pro subscribers only.Sign in or register to be an Insider Pro and access ALL LOCKED articles.
EMPLOYERS HOLDINGS, INC. – 10-Q – Management's Discussion and Analysis of Consolidated Financial Condition and Results of Operations
How long until an ambulance gets to you? Kentucky services struggle with staffing. [Lexington Herald-Leader]
Advisor News
Annuity News
Health/Employee Benefits News
Life Insurance News